DeLLphi-312 is a Phase 3 clinical trial that is testing an investigational drug called tarlatamab. This clinical trial aims to see how safe and effective tarlatamab is at treating patients with small-cell lung cancer (SCLC). Participants will receive either tarlatamab in combination with durvalumab (Imfinzi®), carboplatin and etoposide, or durvalumab, carboplatin and etoposide alone.
Talk to an Amgen Medical Information Healthcare Professional to see if you qualify.
Patients who are 18 years or older
Diagnosed with small-cell lung cancer (SCLC) by tumor sample under a microscope
Extensive-stage small-cell lung cancer (ES-SCLC) is in both lungs or has spread to other areas
Patients who are suitable to receive carboplatin, etoposide and durvalumab regimen as first-line treatment
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
Step 1: Screening
At your first visit(s), you will:
*This may not be needed in all cases. Your doctor will let you know if this is not needed.
If you meet the requirements and decide to join this clinical trial, you will move on to Step 2.
Step 2: Treatment
Approximately 330 participants will be randomly assigned to receive either tarlatamab in combination with durvalumab (Imfinzi®), carboplatin and etoposide (investigational group), or to receive durvalumab, carboplatin and etoposide alone (control group).
The investigational group will:
The control group will:
Step 3: End of treatment
You will continue to receive treatment in this clinical trial based on the results of your bloodwork and imaging. The treatment you receive in this trial or your participation in this clinical trial may end if:
The clinical trial team will schedule a follow-up visit with you approximately 12 weeks after your last trial treatment.
Step 4: Long term follow-up (up to 3 years)
The clinical trial team may follow-up with you by phone or ask you to visit the clinic approximately once every 3 months.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.